Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

Home
/
update
/
details

Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

NextEdge Admin

26 Dec 2024

2 min 42 sec

Innovent Biologics,PD-1 immunotherapy,collaboration

Mankind Pharma Limited, one of India’s largest pharmaceutical companies, has partnered with Innovent Biologics, a leading biopharmaceutical firm, to exclusively license and commercialize sintilimab, a cutting-edge PD-1 immunotherapy, in the Indian market. This collaboration aims to address the growing cancer burden in India and enhance access to innovative treatments.

Cancer is a critical health challenge in India, with its impact projected to reach 29.8 million DALYs by 2025, according to The National Cancer Registry Programme. Sintilimab, marketed as Tyvyt in China, is a high-quality PD-1 monoclonal antibody developed by Innovent and Eli Lilly. By blocking the PD-1/PD-L1 pathway, it reactivates T-cells, enabling the immune system to combat cancer more effectively. Approved in China for eight cancer types, including lung, liver, and gastric cancers, Tyvyt has demonstrated exceptional efficacy and safety, benefiting millions since its launch in 2018.

Under this agreement, Mankind Pharma will manage the registration, import, marketing, sales, and distribution of sintilimab in India, while Innovent will oversee manufacturing and supply. This ensures high-quality standards and product availability. Innovent will receive upfront, regulatory, and milestone payments as part of the deal.

Mankind Pharma’s vast distribution network, comprising over 13,000 stockists and 16,000+ field personnel, will ensure widespread accessibility across urban and rural India. This partnership reflects a shared commitment to transforming cancer care by introducing advanced, affordable treatments.

“At Mankind Pharma, we are dedicated to improving patient outcomes and reshaping oncology care in India,” stated Atish Majumdar, Senior President of Sales & Marketing. Dr. Samuel Zhang, Chief Business Officer of Innovent, emphasized the importance of this collaboration in bringing hope to cancer patients by leveraging Mankind’s extensive expertise and network.